Camp4 Therapeutics Corp
NASDAQ: CAMPCambridge, US · Founded 2015 · Delaware corporation · 4 known investors
Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
Founders & leadership
Camp4 Therapeutics Corp was founded in 2015 by Richard Young.
RY
Richard YoungDirector (Class II)
JM
JOSH MANDEL-BREHMinExecutive
JM
Josh Mandel-BrehminChief Executive Officer and Director (Class III)
Board
MH
MICHAEL HIGGINSBoard director
JC
AN
AMIR NASHATin𝕏Board directorEntrepreneur partner at Polaris Partners focused on healthcare investing and portfolio company executive roles
Investors · 4
Reported raises · per SEC filings
Form D private placements$179.6M disclosed across 3 rounds · 2018–2022
▶$100.5MraisedJun 2022 · 16 investors · BiotechnologyRule 506(b)
▶$100.5MraisedJun 2022 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PAULA RAGANDirector
- STEVE HOLTZMANDirector
- MICHAEL HIGGINSDirector
- RAVI I. THADHANIDirector
- RICHARD YOUNGDirector
- AMIR NASHATDirector
- CALEB MOOREExecutive Officer
- JORGE CONDEDirector
- SHAAN GANDHIDirector
- JOSH MANDEL-BREHMExecutive Officer, Director
- ANN BARBIERExecutive Officer
- ALFICA SEHGALExecutive Officer
- MICHELLE GATESExecutive Officer
- KELLY GOLDExecutive Officer
- DAVID BUMCROTExecutive Officer
- ANDREW J. SCHWABDirector
- JAMES BOYLANDirector
- Amount sold
- $100.5M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45MraisedOct 2021 · 7 investors · BiotechnologyRule 506(b)
▶$45MraisedOct 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JORGE CONDEDirector
- RAVI THADHANIDirector
- ALFICA SEHGALExecutive Officer
- SHAAN GANDHIDirector
- PAULA RAGANDirector
- MICHELLE GATESExecutive Officer
- STEVE HOLTZMANDirector
- CALEB MOOREExecutive Officer
- MICHAEL HIGGINSDirector
- AMIR NASHATDirector
- KELLY GOLDExecutive Officer
- RICHARD YOUNGDirector
- JOSH MANDEL-BREHMExecutive Officer, Director
- ANDY SCHWABDirector
- DAVID BUMCROTExecutive Officer
- Amount sold
- $45M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$34.1MraisedSep 2018 · 6 investors · BiotechnologyRule 506(b)
▶$34.1MraisedSep 2018 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RICHARD YOUNGDirector
- MICHAEL HIGGINSDirector
- JORGE CONDEDirector
- JOSH MANDEL-BREHMExecutive Officer, Director
- AMIR NASHATDirector
- Offering amount
- $34.1M
- Amount sold
- $34.1M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Camp4 Therapeutics Corp do?
- Camp4 Therapeutics develops antisense oligonucleotides targeting regulatory RNAs to increase gene expression and restore healthy protein levels for genetic diseases, with an initial focus on treating SYNGAP1-related developmental and epileptic encephalopathy.
- Who founded Camp4 Therapeutics Corp?
- Camp4 Therapeutics Corp was founded by Richard Young in 2015.
- Who are Camp4 Therapeutics Corp's investors?
- Camp4 Therapeutics Corp's investors include 5AM Ventures, Andreessen Horowitz, Longwood Fund, Polaris Partners.
- How much funding has Camp4 Therapeutics Corp raised?
- Camp4 Therapeutics Corp has disclosed $179.6M raised across 3 rounds.
- Where is Camp4 Therapeutics Corp headquartered?
- Camp4 Therapeutics Corp is headquartered in Cambridge, US.